Annexon (ANNX) Income towards Parent Company (2019 - 2026)
Annexon (ANNX) posted quarterly Income towards Parent Company of -$78.1 million for Q1 2026, down 9.25% year-over-year from -$86.0 million in Q1 2025, and down 15.75% quarter-over-quarter from -$67.4 million in Q4 2025.
Analysis
Annexon (ANNX) Income towards Parent Company (2019 - 2026) Analysis & Trends
Annexon's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 9.25% year-over-year to -$78.1 million; the TTM figure through Mar 2026 stood at -$268.0 million (up 4.7% YoY), while the FY2025 annual figure was -$441.3 million, down 31.76% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$78.1 million, down from -$67.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$40.0 million in Q4 2022, with the low at -$160.9 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$71.5 million (2025), against an average of -$74.2 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company sank 302.25% in 2023, then jumped 64.82% in 2024.
- Annexon's Income towards Parent Company stood at -$40.0 million in 2022, then tumbled by 302.25% to -$160.9 million in 2023, then surged by 64.82% to -$56.6 million in 2024, then fell by 19.16% to -$67.4 million in 2025, then retreated by 15.75% to -$78.1 million in 2026.
- Business Quant data shows ANNX's Income towards Parent Company at -$78.1 million in Q1 2026, -$67.4 million in Q4 2025, and -$62.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Annexon | 974.87 Mn | 974.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.23 Mn |
| Mar 31, 2026 | -46.11 Mn |
| Dec 31, 2025 | -50.21 Mn |
| Sep 30, 2025 | -57.00 Mn |
| Jun 30, 2025 | -51.73 Mn |
| Mar 31, 2025 | -57.51 Mn |
| Dec 31, 2024 | -52.54 Mn |
| Sep 30, 2024 | -39.28 Mn |
| Jun 30, 2024 | -33.57 Mn |
| Mar 31, 2024 | -28.61 Mn |
| Dec 31, 2023 | -29.95 Mn |
| Sep 30, 2023 | -34.73 Mn |
| Jun 30, 2023 | -37.64 Mn |
| Mar 31, 2023 | -41.08 Mn |
| Dec 31, 2022 | -36.67 Mn |
| Sep 30, 2022 | -36.03 Mn |
| Jun 30, 2022 | -37.47 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -37.56 Mn |
| Sep 30, 2021 | -35.60 Mn |